Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

ePoster Display

1113P - Care for neuroendocrine tumor patients, monitored by medical oncologists: Comparative data Europe vs North America

Date

16 Sep 2021

Session

ePoster Display

Presenters

Teodora Kolarova

Citation

Annals of Oncology (2021) 32 (suppl_5): S906-S920. 10.1016/annonc/annonc678

Authors

T. Kolarova1, M. McDonnell2, C.V. Bouvier3, M.E. Pavel4, H. Singh5, J. Howe6, S. Singh7, D. O'Toole8, J. Chen9, S. Leyden10, E. Gellerman11, S. Dureja12, C. Rodien-Louw13, D. Van Genechten14

Author affiliations

  • 1 Executive Director, International Neuroendocrine Cancer Alliance (INCA), 02116 - Boston/US
  • 2 Net Patient Network, NET Patient Network, Dublin/IE
  • 3 Not Applicable, Neuroendocrine Cancer UK, CV32 4JL - Royal Leamington Spa/GB
  • 4 Gastroenterology And Hepatology, Endocrinology Dept, Universitätsklinik Erlangen, 91054 - Erlangen/DE
  • 5 Not Applicable, Prince Court Medical Centre, Kuala Lumpur/MY
  • 6 Surgery Department, University of Iowa Hospitals and Clinics, 52242 - Iowa City/US
  • 7 Medical Oncology, Sunnybrook Odette Cancer Center, Sunnybrook HSC, M4N 3M5 - Toronto/CA
  • 8 Neuroendocrine Tumour Service, St Vincents University Hospital, D04 T6F4 - Dublin/IE
  • 9 Department Of Gastroenterology, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou/CN
  • 10 Na, NeuroEndocrine Cancer Australia, Blairgowrie/AU
  • 11 Na, NET Research Foundation, Boston/US
  • 12 Nuclear Medicine And Molecular Therapy, Action Cancer Hospital, 110063 - New Delhi/IN
  • 13 Na, APTED, Lyon/FR
  • 14 Na, vzw NET & MEN Kanker Belgium, Kortrijk/BE
More

Abstract 1113P

Background

The Survey of Challenges in Access to Diagnostics and Treatment for NET Patients (SCAN) measured healthcare delivery to neuroendocrine tumor (NET) patients globally.

Methods

This analysis focused on the medical care received by NET patients who most often visited a medical oncologist (MO) comparing Europe and North America.

Results

1016 NET patients (43% of global sample, N=2359) reported a MO as the HCP most often visited for ongoing monitoring. These patients were mostly from two geographic areas: Europe (EU) [40%, 409/1016] and North America (NA) [40%, 410/1016]. 55% from EU (223/409) and 61% from NA (252/410) had Stage IV disease at diagnosis – both significantly higher than the percentage reported by patients globally (46%, 1077/2359, p<0.0001). Conventional imaging (EU 79%, 313/395; NA: 83%, 338/407) and Chromogranin A (EU 64%, 252/395, NA 60%, 243/407) were most commonly used for ongoing monitoring. 68Gallium DOTA-PET CT (EU: 30%, 119/395; NA 37%, 152/407, p<0.0001), other blood tests ( fasting serum glucose, fasting gastrin, glucagon, VIP; EU: 31%, 122/395; NA: 42%, 172/407, p<0.0001) and urine 5-HIAA (EU 29%, 116/395, NA: 35%, 142/407, p<0.0001) were also used, significantly more frequently in NA. MOs were the most often visited specialists for follow-up, although GPs/family doctors (EU, 48%, 197/409; NA: 44%, 181/410) and nurses (EU: 27%, 111/409; NA: 22%, 91/410) were also involved in the follow-up. In case of a third HCP involved, in EU this was most often a nuclear medicine specialist (23%) or a radiologist (20%), while in NA this was a surgeon (25%). Multidisciplinary teams (MDT) were rarely used both in EU (35%, 143/409) and NA (32%, 131/410). This patient sub-group’s key recommendation was to have more healthcare professionals knowledgeable in NETs (EU: 58%, 237/409, NA: 71%, 291/410 p<0.0001).

Conclusions

MOs are the leading HCPs for ongoing monitoring for almost half of NET patients globally. A global standard for NET monitoring and higher expertise in NETs among HCPs is needed, as data indicate significant differences in therapeutic and follow-up procedures and low usage of the multidisciplinary approach even in the EU and NA, the leading geographic areas for NET medical care.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

International Neuroendocrine Cancer Alliance (INCA).

Funding

Ipsen, Novartis, ITM.

Disclosure

T. Kolarova: Financial Interests, Institutional, Advisory Board, null: Ipsen; Financial Interests, Institutional, Invited Speaker, null: Aptitude Health; Financial Interests, Personal, Other, Executive Director: International Neuroendocrine Cancer Alliance; Financial Interests, Institutional, Funding, null: Ipsen; Financial Interests, Institutional, Funding, INCA receives funding for its activities from pharma companies: Novartis; Financial Interests, Institutional, Funding, null: AAA; Financial Interests, Institutional, Funding, null: ITM; Non-Financial Interests, Advisory Role, null: European Cancer Organisation; Non-Financial Interests, Other, Active collaborator: WECAN; Non-Financial Interests, Member, Institutional or personal membership in the above listed organizations: UICC, NORD, ENETS, NANETS, E.C.O., WECAN. M. McDonnell: Non-Financial Interests, Other, Current Treasurer and President-Elect for 2022 in this global patient advocacy non-profit organisation: INCA; Non-Financial Interests, Other, Chairperson of the National Patient Advocacy Group for Neuroendocrine Cancer in Ireland: NET Patient Network Ireland. C.V. Bouvier: Financial Interests, Institutional, Advisory Board, INCA reimbursed for time given to AAA to review patient-facing publications: AAA; Non-Financial Interests, Member of the Board of Directors, Current President 2020-2022 of INCA and board member: INCA. M.E. Pavel: Financial Interests, Personal, Invited Speaker: AAA; Financial Interests, Personal, Advisory Board: AAA; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Invited Speaker: Boehringer Ingelheím; Financial Interests, Personal, Advisory Board: Crinetics; Financial Interests, Personal, Invited Speaker: IPSEN; Financial Interests, Personal, Advisory Board: Riemser; Financial Interests, Institutional, Other, Fees for coordinating PI: IPSEN; Financial Interests, Institutional, Other, Fees for study conduct: ITM; Financial Interests, Institutional, Other, Local PI, fees for study conduct: Novartis. H. Singh: Financial Interests, Personal, Other, Moderator for Webinar: Novartis Corporation [M] Sdn Bhd; Non-Financial Interests, Member, Leadership Role, Non-remunerated position: Asia Pacific Neuroendocrine Tumour Society; Non-Financial Interests, Member: Asia Pacific Hepato-Pancreato-Biliary Association; Non-Financial Interests, Leadership Role: Asia-Pacific Neuroendocrine Tumour Society; Non-Financial Interests, Member: International Hepato-Pancreato-Biliary Association. S. Singh: Financial Interests, Institutional, Research Grant: Novartis/AAA; Financial Interests, Personal, Advisory Board: Ipsen; Financial Interests, Institutional, Research Grant: Ipsen. D. O'Toole: Financial Interests, Institutional, Speaker’s Bureau: Ipsen; Financial Interests, Institutional, Speaker’s Bureau, Speaker bureau & advisory board: Novartis; Non-Financial Interests, Institutional, Research Grant, Research grants while working in Beaujon, Clichy France; Also research grant in St Vincent's University Hospital (funding of a research registrar): Ipsen; Financial Interests, Personal and Institutional, Funding, Funded my MD research salary in 1996 to 1998 related to Helicobacter pylori infection: Wyeth lederle; Non-Financial Interests, Other, Pats Chair of ENETS; Current Executive Committee member of ENETS; Advisory board member of INCA: ENETS, INCA. J. Chen: Financial Interests, Personal, Invited Speaker: Hutchison Medipharma Limited; Financial Interests, Personal, Invited Speaker: Ipsen; Financial Interests, Personal, Invited Speaker: Novartis; Financial Interests, Personal, Invited Speaker: Pfizer. S. Leyden: Financial Interests, Personal, Full or part-time Employment, Co-founder and CEO: Neuroendocrine Cancer Australia. E. Gellerman: Financial Interests, Personal, Full or part-time Employment, am the CEO of the Foundation, a 501(c)3 charity that funds NET research: Neuroendocrine Tumor Research Foundation; Non-Financial Interests, Member, I am a member of The North American Neuroendocrine Tumor Society (NANETS): NANETS; Non-Financial Interests, Member, NETRF is a member of the National Organization for Rare Diseases (NORD) and I am on the Rare Cancer Coalition.: NORD; Other, Institutional, Invited Speaker, NETRF has received funding from these companies to help support patient education activities or research grants awarded to other institutions: Ipsen, Advanced Accelerator Applications, TerSera, Lantheus, Crinetics,. C. Rodien-Louw: Financial Interests, Institutional, Research Grant, INCA: Ipsen; Financial Interests, Institutional, Research Grant, INCA: AAA; Financial Interests, Institutional, Research Grant: APTED. D. Van Genechten: Financial Interests, Institutional, Research Grant: Novartis Pharmaceuticals Corporation; Financial Interests, Institutional, Research Grant: Ipsen Pharma; Non-Financial Interests, Institutional, Member of the Board of Directors: vzw NET & MEN Kanker Belgium. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.